Yarbrough Capital LLC Has $638,000 Stock Position in Insulet Corporation $PODD

Yarbrough Capital LLC lowered its position in Insulet Corporation (NASDAQ:PODD) by 49.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,068 shares of the medical instruments supplier’s stock after selling 1,994 shares during the quarter. Yarbrough Capital LLC’s holdings in Insulet were worth $638,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Kozak & Associates Inc. bought a new position in Insulet in the second quarter worth $32,000. Golden State Wealth Management LLC lifted its holdings in shares of Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 69 shares during the period. Trust Co. of Toledo NA OH bought a new position in shares of Insulet during the 2nd quarter worth about $35,000. Osterweis Capital Management Inc. acquired a new stake in shares of Insulet during the 2nd quarter valued at about $51,000. Finally, NewEdge Advisors LLC increased its stake in Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 64 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Evercore ISI assumed coverage on shares of Insulet in a research note on Tuesday, December 16th. They set an “outperform” rating and a $370.00 price target for the company. Zacks Research upgraded Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Stifel Nicolaus began coverage on Insulet in a research report on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price target on the stock. Truist Financial dropped their price objective on Insulet from $412.00 to $390.00 and set a “buy” rating for the company in a research note on Thursday, December 18th. Finally, Oppenheimer boosted their target price on shares of Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $379.00.

Insulet Stock Down 1.0%

Shares of NASDAQ PODD opened at $284.24 on Thursday. Insulet Corporation has a 12-month low of $230.05 and a 12-month high of $354.88. The firm’s 50-day simple moving average is $311.14 and its 200 day simple moving average is $312.57. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. The company has a market cap of $20.00 billion, a price-to-earnings ratio of 82.39, a price-to-earnings-growth ratio of 2.02 and a beta of 1.37.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The firm had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. During the same quarter last year, the company posted $1.08 EPS. The company’s quarterly revenue was up 29.9% compared to the same quarter last year. On average, research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.